The ALS Association’s Walk to Defeat ALS fundraising event this year is marking 25 years of bringing together people with amyotrophic lateral sclerosis (ALS) and their families to offer support and raise funds for advancing research and improving care for those living with the disease. With a total…
The ALS Association has launched a free resource to help people with amyotrophic lateral sclerosis (ALS) and their families navigate health insurance denials and appeals — with the tool’s goal to help patients get coverage for critical care. Dubbed the ALS Insurance Navigator, the tool delivers detailed…
A clinical trial that will test a noninvasive, nerve-modulating device called MyoRegulator — designed to slow disease progression in people with amyotrophic lateral sclerosis (ALS) — has been cleared to start patient enrollment in the U.S. That green light, from an Institutional Review Board, will allow Pathmaker…
Neuropeutics has partnered with LifeArc to advance work on a small molecule therapy against TDP-43 clumping as a potential disease-modifying treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Studies in cellular and animal models found the candidate treatment,…
Ncardia has launched a stem cell-derived model of human microglia to advance research into neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), where these cells play an important role. Microglia, the resident immune cells in the brain, help support the function of nerve cells, but if they become overly…
Bravyl (oral fasudil), an experimental therapy Woolsey Pharmaceuticals is developing for amyotrophic lateral sclerosis (ALS), significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of the disease. New data was presented at the University of Denver during the International Symposium on ALS/MND, which took…
Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics to combine efforts to advance both companies’ drug portfolios. The combined company will focus on moving AstroRx and a diabetes drug being developed by Kadimastem through clinical trials. A Phase…
Woolsey Pharmaceuticals has received three new U.S. patents covering innovations related to Bravyl (oral fasudil), its investigational amyotrophic lateral sclerosis (ALS) medication. The patents cover the use of oral fasudil to slow the progression of sporadic ALS, as well as solid and liquid formulations of fasudil for people…
A Texas Children’s Hospital investigator has received a $2.4 million grant for a study that seeks to understand whether mechanisms used by bacteria to hide from the immune system can be explored to ease inflammation in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Steven Boeynaems, PhD, an investigator…
Avextra is set to launch a Phase 2 trial in Italy to test a cannabis-based oral medication for the management of symptoms in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The announcement comes after clearance from both the Italian Medicines Agency and the Ministry of…
Get regular updates to your inbox.
